NCT02212015

Evaluation of Votrient in Angiosarcoma

Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Heidelberg University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.

Detailed description

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single arm phase II study was designed to evaluate the clinical efficacy and safety of the experimental combination of pazopanib with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory checks as defined in protocol, toxicity/adverse event assessment according Eastern Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (= day 1 of the next cycle).

Conditions

• Angiosarcoma

Interventions

Type	Name	Description
DRUG	Pazopanib + Paclitaxel	pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.

Timeline

• Start date: 2014-07-01
• Primary completion: 2019-12-31
• Completion: 2020-07-01
• First posted: 2014-08-08
• Last updated: 2022-03-22
• Results posted: 2022-03-22

Locations

10 sites across 2 countries: Austria, Germany